Washington, DC – Tomorrow, the Supreme Court will hear oral arguments in the case Alliance for Hippocratic Medicine v FDA, challenging the FDA’s approval of mifepristone, one of two drugs used in medication abortion. If the plaintiffs are successful, this case could result in a functional ban on the use of telehealth in abortion care nationwide and severely limit access to medication abortion care, particularly for low-income, rural, and other underserved communities.
“We hope that the Supreme Court will recognize the decades of studies showing mifepristone is safe and effective. The National Health Law Program will continue to monitor this case and advocate for comprehensive insurance coverage of mifepristone to ensure equitable abortion access,” says Cat Duffy, Policy Analyst at the National Health Law Program.
For more information on the importance of telehealth and medication abortion access, please see these resources:
- Asynchronous Telehealth Abortion Services for Medicaid Enrollees
- Report: Progress and Gaps in Medicaid Coverage of Telehealth Medication Abortion Services in Six States
- FAQ: Insurance Coverage for Pharmacy-Dispensed Medication Abortion
